Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITY study of tremelimumab + durvalumab for MSI-high resectable gastric or gastroesophageal junction cancer
2020-003440-92Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Pathological complete response and ctDNA negativity. Started May 2021; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2020-003440-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003440-92.